These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37819505)

  • 1. Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study.
    Mease PJ; Gladman DD; Poddubnyy D; Chakravarty SD; Shawi M; Kollmeier AP; Xu XL; Xu S; Deodhar A; Baraliakos X
    Rheumatol Ther; 2023 Dec; 10(6):1637-1653. PubMed ID: 37819505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies.
    Mease PJ; Helliwell PS; Gladman DD; Poddubnyy D; Baraliakos X; Chakravarty SD; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Agarwal P; Zhou B; Sweet K; Shawi M; Karyekar CS; Deodhar A; van der Heijde D
    Lancet Rheumatol; 2021 Oct; 3(10):e715-e723. PubMed ID: 38287608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
    Gladman DD; Mease PJ; Bird P; Soriano ER; Chakravarty SD; Shawi M; Xu S; Quinn ST; Gong C; Leibowitz E; Poddubnyy D; Tam LS; Helliwell PS; Kavanaugh A; Deodhar A; Østergaard M; Baraliakos X
    Trials; 2022 Sep; 23(1):743. PubMed ID: 36064592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.
    Helliwell PS; Gladman DD; Chakravarty SD; Kafka S; Karyekar CS; You Y; Campbell K; Sweet K; Kavanaugh A; Gensler LS
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32209721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials.
    Mease P; Korotaeva T; Shesternya P; Kokhan M; Rukavitsyn A; Vasilchenkov D; Sharaf M; Lavie F; Deodhar A
    Rheumatol Ther; 2024 Dec; 11(6):1551-1567. PubMed ID: 39320583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies.
    Baraliakos X; Ranza R; Östör A; Ciccia F; Coates LC; Rednic S; Walsh JA; Douglas K; Gao T; Kato K; Song IH; Ganz F; Deodhar A
    Arthritis Res Ther; 2023 Apr; 25(1):56. PubMed ID: 37038159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2.
    Deodhar A; Gladman D; Bolce R; Sandoval D; Park SY; Leage SL; Nash P; Poddubnyy D
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231189005. PubMed ID: 37645684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study.
    Ritchlin CT; Mease PJ; Boehncke WH; Tesser J; Chakravarty SD; Rampakakis E; Shawi M; Schiopu E; Merola JF; McInnes IB; Deodhar A
    Clin Rheumatol; 2024 Aug; 43(8):2551-2563. PubMed ID: 38844682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.
    Rahman P; Mease PJ; Helliwell PS; Deodhar A; Gossec L; Kavanaugh A; Kollmeier AP; Hsia EC; Zhou B; Lin X; Shawi M; Karyekar CS; Han C
    Arthritis Res Ther; 2021 Jul; 23(1):190. PubMed ID: 34261541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.
    Coates LC; Gossec L; Zimmermann M; Shawi M; Rampakakis E; Shiff NJ; Kollmeier AP; Xu XL; Nash P; Mease PJ; Helliwell PS
    RMD Open; 2024 Mar; 10(1):. PubMed ID: 38531621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis.
    Gottlieb AB; McInnes IB; Rahman P; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; Lavie F; Mease PJ
    RMD Open; 2023 Feb; 9(1):. PubMed ID: 36828643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
    Curtis JR; McInnes IB; Rahman P; Gladman DD; Peterson S; Agarwal P; Yang F; Kollmeier AP; Hsia EC; Shiff NJ; Zhou B; Han C; Shawi M; Tillett W; Mease PJ
    Adv Ther; 2022 Oct; 39(10):4613-4631. PubMed ID: 35947349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies.
    Baraliakos X; Gladman DD; Chakravarty SD; Gong C; Shawi M; Rampakakis E; Kishimoto M; Soriano ER; Mease PJ
    Rheumatol Adv Pract; 2024; 8(2):rkae058. PubMed ID: 38765190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies.
    Ritchlin CT; Mease PJ; Boehncke WH; Tesser J; Schiopu E; Chakravarty SD; Kollmeier AP; Xu XL; Shawi M; Jiang Y; Sheng S; Wang Y; Xu S; Merola JF; McInnes IB; Deodhar A
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35296534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
    Curtis JR; McInnes IB; Rahman P; Gladman DD; Yang F; Peterson S; Agarwal P; Kollmeier AP; Hsia EC; Han C; Shiff NJ; Shawi M; Tillett W; Mease PJ
    Adv Ther; 2022 Oct; 39(10):4632-4644. PubMed ID: 35947348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.
    Ritchlin CT; Coates LC; Mease PJ; van der Heijde D; Song J; Jiang Y; Shawi M; Kollmeier AP; Rahman P
    Trials; 2023 Jan; 24(1):22. PubMed ID: 36627711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study.
    Ritchlin CT; Deodhar A; Boehncke WH; Soriano ER; Kollmeier AP; Xu XL; Zazzetti F; Shawi M; Jiang Y; Sheng S; Helliwell PS
    ACR Open Rheumatol; 2023 Mar; 5(3):149-164. PubMed ID: 36762512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2).
    Kavanaugh A; Puig L; Gottlieb AB; Ritchlin C; You Y; Li S; Song M; Randazzo B; Rahman P; McInnes IB
    Ann Rheum Dis; 2016 Nov; 75(11):1984-1988. PubMed ID: 27098404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
    Deodhar A; Shiff NJ; Gong C; Chan EKH; Hsia EC; Lo KH; Akawung A; Kim L; Xu S; Reveille JD
    Rheumatol Ther; 2023 Aug; 10(4):983-999. PubMed ID: 37322274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials.
    Curtis JR; Deodhar A; Soriano ER; Rampakakis E; Shawi M; Shiff NJ; Han C; Tillett W; Gladman DD
    Rheumatol Ther; 2024 Dec; 11(6):1501-1517. PubMed ID: 39261446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.